283 related articles for article (PubMed ID: 29786783)
1. A xenograft model for venous malformation.
Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.
Boscolo E; Limaye N; Huang L; Kang KT; Soblet J; Uebelhoer M; Mendola A; Natynki M; Seront E; Dupont S; Hammer J; Legrand C; Brugnara C; Eklund L; Vikkula M; Bischoff J; Boon LM
J Clin Invest; 2015 Sep; 125(9):3491-504. PubMed ID: 26258417
[TBL] [Abstract][Full Text] [Related]
3. A Xenograft Model for Venous Malformation.
Goines J; Boscolo E
Methods Mol Biol; 2021; 2206():179-192. PubMed ID: 32754818
[TBL] [Abstract][Full Text] [Related]
4. Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation.
Li X; Cai Y; Goines J; Pastura P; Brichta L; Lane A; Le Cras TD; Boscolo E
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):496-512. PubMed ID: 30626204
[TBL] [Abstract][Full Text] [Related]
5. A Patient-Derived Xenograft Model for Venous Malformation.
Schrenk S; Goines J; Boscolo E
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32597867
[TBL] [Abstract][Full Text] [Related]
6. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.
Le Cras TD; Goines J; Lakes N; Pastura P; Hammill AM; Adams DM; Boscolo E
Angiogenesis; 2020 Aug; 23(3):425-442. PubMed ID: 32350708
[TBL] [Abstract][Full Text] [Related]
7. AKT/FOXO1 axis links cross-talking of endothelial cell and pericyte in TIE2-mutated venous malformations.
Si Y; Huang J; Li X; Fu Y; Xu R; Du Y; Cheng J; Jiang H
Cell Commun Signal; 2020 Aug; 18(1):139. PubMed ID: 32867785
[TBL] [Abstract][Full Text] [Related]
8. Somatic Activating PIK3CA Mutations Cause Venous Malformation.
Limaye N; Kangas J; Mendola A; Godfraind C; Schlögel MJ; Helaers R; Eklund L; Boon LM; Vikkula M
Am J Hum Genet; 2015 Dec; 97(6):914-21. PubMed ID: 26637981
[TBL] [Abstract][Full Text] [Related]
9. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
[TBL] [Abstract][Full Text] [Related]
10. Development of Molecular Therapies for Venous Malformations.
Kangas J; Nätynki M; Eklund L
Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():6-19. PubMed ID: 29668117
[TBL] [Abstract][Full Text] [Related]
11. Constitutive Active Mutant TIE2 Induces Enlarged Vascular Lumen Formation with Loss of Apico-basal Polarity and Pericyte Recruitment.
Cai Y; Schrenk S; Goines J; Davis GE; Boscolo E
Sci Rep; 2019 Aug; 9(1):12352. PubMed ID: 31451744
[TBL] [Abstract][Full Text] [Related]
12. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
[TBL] [Abstract][Full Text] [Related]
13. CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations.
Moneghini L; Tosi D; Graziani D; Caretti A; Colletti G; Baraldini V; Cattaneo E; Spaccini L; Zocca A; Bulfamante GP
Hum Pathol; 2020 May; 99():98-106. PubMed ID: 32272124
[TBL] [Abstract][Full Text] [Related]
14. Common and specific effects of TIE2 mutations causing venous malformations.
Nätynki M; Kangas J; Miinalainen I; Sormunen R; Pietilä R; Soblet J; Boon LM; Vikkula M; Limaye N; Eklund L
Hum Mol Genet; 2015 Nov; 24(22):6374-89. PubMed ID: 26319232
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive phenotypic and genomic characterization of venous malformations.
Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E
Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816
[TBL] [Abstract][Full Text] [Related]
16. Review of the endothelial pathogenic mechanism of TIE2-related venous malformation.
Du Z; Zheng J; Zhang Z; Wang Y
J Vasc Surg Venous Lymphat Disord; 2017 Sep; 5(5):740-748. PubMed ID: 28818232
[TBL] [Abstract][Full Text] [Related]
17. Genetic landscape of common venous malformations in the head and neck.
Du Z; Liu JL; You YH; Wang LZ; He J; Zheng JW; Zhang ZY; Wang YA
J Vasc Surg Venous Lymphat Disord; 2021 Jul; 9(4):1007-1016.e7. PubMed ID: 33248299
[TBL] [Abstract][Full Text] [Related]
18. Somatic PIK3CA mutations as a driver of sporadic venous malformations.
Castel P; Carmona FJ; Grego-Bessa J; Berger MF; Viale A; Anderson KV; Bague S; Scaltriti M; Antonescu CR; Baselga E; Baselga J
Sci Transl Med; 2016 Mar; 8(332):332ra42. PubMed ID: 27030594
[TBL] [Abstract][Full Text] [Related]
19. Classification and Tie2 mutations in spinal and soft tissue vascular anomalies.
Zhou M; Jiang R; Zhao G; Wang L; Wang H; Li W; Li Y; Du X; Bai J
Gene; 2015 Oct; 571(1):91-6. PubMed ID: 26115772
[TBL] [Abstract][Full Text] [Related]
20. ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component.
Jauhiainen S; Ilmonen H; Vuola P; Rasinkangas H; Pulkkinen HH; Keränen S; Kiema M; Liikkanen JJ; Laham-Karam N; Laidinen S; Beter M; Aavik E; Lappalainen K; Lohi J; Aronniemi J; Örd T; Kaikkonen MU; Salminen P; Tukiainen E; Ylä-Herttuala S; Laakkonen JP
Elife; 2023 May; 12():. PubMed ID: 37199488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
